Preliminary safety and efficacy of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in patients (pts) with hairy cell leukemia (HCL).
Jeffrey Alan Jones
Consultant or Advisory Role - Pharmacyclics
Research Funding - Pharmacyclics
Leslie A. Andritsos
No relevant relationships to disclose
David M Lucas
No relevant relationships to disclose
Gerard Lozanski
No relevant relationships to disclose
Terri Hutchinson
No relevant relationships to disclose
Jennifer L. Sexton
No relevant relationships to disclose
Pamela Jo Harris
No relevant relationships to disclose
Michael R. Grever
No relevant relationships to disclose